Epsilon M&A Deal Report - Aurelia Bioscience

Transaction Multiples for the Valuation of Private Companies

Charnwood Molecular > Aurelia Bioscience

Announced Date : 21 June 2021

Type : Acquisition of Majority Stake

Deal Value : Yes

Acquirer : Charnwood Molecular

Target: Aurelia Bioscience

Target Country: United Kingdom

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> Aurelia Bioscience Ltd is a contract research organisation 

No EMAT : 114304

Transaction multiples available

EV/Sales EV/Gross Profit EV/EBITDA EV/EBIT Eq/PBT P/E Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating **

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1226

Example of comparable transactions on EMAT (same sub-sector):

Date Acquirer Target Country Multiples See details
31/03/2021 Charles River Discovery Research Services UK Retrogenix United Kingdom 0
18/07/2023 Groupe Vabel Laboratoires Sarbec France 0

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report
About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.

Subscribe to EMAT database